KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $3.4 million.

  • Emergent BioSolutions' Capital Expenditures fell 4137.93% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year decrease of 6441.72%. This contributed to the annual value of $22.9 million for FY2024, which is 5562.02% down from last year.
  • Per Emergent BioSolutions' latest filing, its Capital Expenditures stood at $3.4 million for Q3 2025, which was down 4137.93% from $2.9 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Capital Expenditures high stood at $179.4 million for Q3 2022, and its period low was $1.7 million during Q4 2024.
  • Over the past 5 years, Emergent BioSolutions' median Capital Expenditures value was $12.5 million (recorded in 2023), while the average stood at $30.7 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 22500.0% in 2022, then crashed by 9297.66% in 2023.
  • Emergent BioSolutions' Capital Expenditures (Quarter) stood at $45.8 million in 2021, then surged by 291.7% to $179.4 million in 2022, then tumbled by 93.65% to $11.4 million in 2023, then tumbled by 85.09% to $1.7 million in 2024, then soared by 100.0% to $3.4 million in 2025.
  • Its last three reported values are $3.4 million in Q3 2025, $2.9 million for Q2 2025, and $3.6 million during Q1 2025.